810659-05-3

Basic information

• Product Name: Cyclohexanemethanamine, 4,4-difluoro-
• Synonyms: Cyclohexanemethanamine, 4,4-difluoro-;C-(4,4-Difluoro-cyclohexyl)-methylamine;(4,4-Difluorocyclohexyl)methylamine;1-(Aminomethyl)-4,4-difluorocyclohexane;4,4-difluoro-cyclohexaneMethanaMine;(4,4-difluorocyclohexyl)methanamine;(4,4-Difluorocyclohexyl)
• CAS NO: 810659-05-3
• Molecular Formula: C₇H₁₃F₂N
• Molecular Weight: 149.1816
• Product Categories: Drug Intermediates
• Mol File: 810659-05-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 171℃
• Flash Point: 69℃
• Appearance: /
• Density: 1.05
• Vapor Pressure: 1.45mmHg at 25°C
• Refractive Index: 1.427
• CAS DataBase Reference: Cyclohexanemethanamine, 4,4-difluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanemethanamine, 4,4-difluoro-(810659-05-3)
• EPA Substance Registry System: Cyclohexanemethanamine, 4,4-difluoro-(810659-05-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 810659-05-3(Hazardous Substances Data)

Usage

General Description

Cyclohexanemethanamine, 4,4-difluoro-, also known as 4,4-difluoro cyclohexanemethanamine, is a type of fluorinated chemical compound with the molecular formula C7H12F2N. This chemical mainly exists as a clear liquid. Upon inhalation, ingestion, or skin contact, the chemical may be harmful as it may cause severe health issues. It may irritate the skin, eyes, and respiratory tract. Being a reactive compound, it may react in various manners, such as combustion or degradation, hence should be handled carefully. Generally, this chemical is used in organic synthesis in the field of pharmaceuticals and agrochemicals.

InChI:InChI=1/C7H13F2N/c8-7(9)3-1-6(5-10)2-4-7/h6H,1-5,10H2

Upstream product

• 809273-70-9 (4-oxo-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 809273-64-1 tert-butyl (4,4-difluorocyclohexyl)methylcarbamate 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1122648-78-5 4-(azidomethyl)-1,1-difluorocyclohexane 
• 927209-98-1 4,4-difluorocyclohexanecarboxamide 
• 922728-21-0 4,4-difluorocyclohexane-1-carbonitrile 
• 176251-49-3 8,8-difluoro-1,4-dioxaspiro[4,5]decane 
• 60-29-7 diethyl ether 
• 22515-18-0 4,4-difluorocyclohexanone 

Downstream Products

• 1062653-75-1 C₂₀H₂₃ClF₂N₄O 
• 1361951-02-1 N-((4,4-difluorocyclohexyl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 927210-00-2 5-bromo-7-chloro-2-[(4,4-difluorocyclohexyl)methyl]isoindolin-1-one 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

A PROCESS FOR PRODUCING [(4,4- DIF LUOROCYCLOHEXYL) METHYL] AMINE

A process for preparing a compound of formula I wherein R1 is H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, -OH, or amino; and n, m, and p are independently selected from 0, 1 and 2; which process comprises reacting a